156 related articles for article (PubMed ID: 7821191)
1. Galactosemia produces ARI-preventable nodal changes similar to those of diabetic neuropathy.
Kamijo M; Basso M; Cherian PV; Hohman TC; Sima AA
Diabetes Res Clin Pract; 1994 Sep; 25(2):117-29. PubMed ID: 7821191
[TBL] [Abstract][Full Text] [Related]
2. Effect of long-term treatment with a new aldose reductase inhibitor, (2S,4S)-6-fluoro-2',5'-dioxospiro-[chroman-4,4'-imidazolidine]-2-carbox amide (SNK-860), on peripheral neuropathy in streptozotocin-induced diabetic rats.
Kato N; Mizuno K; Matsubara A; Nakano K; Kurono M; Yagihashi S
J Diabetes Complications; 1994; 8(1):27-32. PubMed ID: 8167384
[TBL] [Abstract][Full Text] [Related]
3. Effects of 15-month aldose reductase inhibition with fidarestat on the experimental diabetic neuropathy in rats.
Kato N; Mizuno K; Makino M; Suzuki T; Yagihashi S
Diabetes Res Clin Pract; 2000 Oct; 50(2):77-85. PubMed ID: 10960717
[TBL] [Abstract][Full Text] [Related]
4. An aldose reductase inhibitor and aminoguanidine prevent vascular endothelial growth factor expression in rats with long-term galactosemia.
Frank RN; Amin R; Kennedy A; Hohman TC
Arch Ophthalmol; 1997 Aug; 115(8):1036-47. PubMed ID: 9258227
[TBL] [Abstract][Full Text] [Related]
5. The role of cyclic adenosine 3',5'-monophosphate and polyol metabolism in diabetic neuropathy.
Shindo H; Tawata M; Aida K; Onaya T
J Clin Endocrinol Metab; 1992 Feb; 74(2):393-8. PubMed ID: 1370506
[TBL] [Abstract][Full Text] [Related]
6. Preventive effect of long-term aldose reductase inhibition (ponalrestat) on nerve conduction and sural nerve structure in the spontaneously diabetic Bio-Breeding rat.
Sima AA; Prashar A; Zhang WX; Chakrabarti S; Greene DA
J Clin Invest; 1990 May; 85(5):1410-20. PubMed ID: 2110189
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats.
Cameron NE; Cotter MA; Basso M; Hohman TC
Diabetologia; 1997 Mar; 40(3):271-81. PubMed ID: 9084964
[TBL] [Abstract][Full Text] [Related]
8. Effects of long-term aldose reductase inhibition on development of experimental diabetic neuropathy. Ultrastructural and morphometric studies of sural nerve in streptozocin-induced diabetic rats.
Yagihashi S; Kamijo M; Ido Y; Mirrlees DJ
Diabetes; 1990 Jun; 39(6):690-6. PubMed ID: 2140802
[TBL] [Abstract][Full Text] [Related]
9. Effect of aldose reductase inhibition on nerve conduction velocity and resistance to ischemic conduction block in experimental diabetes.
Price DE; Airey CM; Alani SM; Wales JK
Diabetes; 1988 Jul; 37(7):969-73. PubMed ID: 3133261
[TBL] [Abstract][Full Text] [Related]
10. Effect of a potent new aldose reductase inhibitor, (5-(3-thienyltetrazol-1-yl)acetic acid (TAT), on diabetic neuropathy in rats.
Hotta N; Kakuta H; Fukasawa H; Koh N; Sakakibara F; Nakamura J; Hamada Y; Wakao T; Hara T; Mori K
Diabetes Res Clin Pract; 1995 Feb; 27(2):107-17. PubMed ID: 7607048
[TBL] [Abstract][Full Text] [Related]
11. Nerve fiber regeneration following axotomy in the diabetic biobreeding Worcester rat: the effect of ARI treatment.
Kamijo M; Merry AC; Akdas G; Cherian PV; Sima AA
J Diabetes Complications; 1996; 10(4):183-91. PubMed ID: 8835917
[TBL] [Abstract][Full Text] [Related]
12. Interactions between essential fatty acid, prostanoid, polyol pathway and nitric oxide mechanisms in the neurovascular deficit of diabetic rats.
Cameron NE; Cotter MA; Hohman TC
Diabetologia; 1996 Feb; 39(2):172-82. PubMed ID: 8635669
[TBL] [Abstract][Full Text] [Related]
13. Osmotically-induced nerve taurine depletion and the compatible osmolyte hypothesis in experimental diabetic neuropathy in the rat.
Stevens MJ; Lattimer SA; Kamijo M; Van Huysen C; Sima AA; Greene DA
Diabetologia; 1993 Jul; 36(7):608-14. PubMed ID: 8359577
[TBL] [Abstract][Full Text] [Related]
14. Overt diabetic neuropathy: repair of axo-glial dysjunction and axonal atrophy by aldose reductase inhibition and its correlation to improvement in nerve conduction velocity.
Sima AA; Prashar A; Nathaniel V; Bril V; Werb MR; Greene DA
Diabet Med; 1993 Mar; 10(2):115-21. PubMed ID: 8458187
[TBL] [Abstract][Full Text] [Related]
15. Transgenic mice overexpressing aldose reductase in Schwann cells show more severe nerve conduction velocity deficit and oxidative stress under hyperglycemic stress.
Song Z; Fu DT; Chan YS; Leung S; Chung SS; Chung SK
Mol Cell Neurosci; 2003 Aug; 23(4):638-47. PubMed ID: 12932443
[TBL] [Abstract][Full Text] [Related]
16. Effects of a new aldose reductase inhibitor, (2S, 4S)-6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazolidine]-2-ca rboxamid e (SNK-860), on the slowing of motor nerve conduction velocity and metabolic abnormalities in the peripheral nerve in acute streptozotocin-induced diabetic rats.
Mizuno K; Kato N; Matsubara A; Nakano K; Kurono M
Metabolism; 1992 Oct; 41(10):1081-6. PubMed ID: 1328819
[TBL] [Abstract][Full Text] [Related]
17. Prevention of defects of axonal transport and nerve conduction velocity by oral administration of myo-inositol or an aldose reductase inhibitor in streptozotocin-diabetic rats.
Mayer JH; Tomlinson DR
Diabetologia; 1983 Nov; 25(5):433-8. PubMed ID: 6197336
[TBL] [Abstract][Full Text] [Related]
18. Effect of the aldose reductase inhibitor tolrestat on nerve conduction velocity, Na/K ATPase activity, and polyols in red blood cells, sciatic nerve, kidney cortex, and kidney medulla of diabetic rats.
Raccah D; Coste T; Cameron NE; Dufayet D; Vague P; Hohman TC
J Diabetes Complications; 1998; 12(3):154-62. PubMed ID: 9618071
[TBL] [Abstract][Full Text] [Related]
19. Peripheral nerve structure and function in long-term galactosemic dogs: morphometric and electron microscopic analyses.
Sugimoto K; Kasahara T; Yonezawa H; Yagihashi S
Acta Neuropathol; 1999 Apr; 97(4):369-76. PubMed ID: 10208276
[TBL] [Abstract][Full Text] [Related]
20. Nodal Na(+)-channel displacement is associated with nerve-conduction slowing in the chronically diabetic BB/W rat: prevention by aldose reductase inhibition.
Cherian PV; Kamijo M; Angelides KJ; Sima AA
J Diabetes Complications; 1996; 10(4):192-200. PubMed ID: 8835918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
